TransMedics Group, Inc.

TransMedics Group, Inc.

TMDXNYSE / NASDAQHealthcareMid cap

$85.25-$8.77 (-9.3%)

Last close · Data as of Nov 20, 2026

Market cap
$2.5B
P/E
13.0x
EV / EBITDA
16.8x
Revenue
$605.5M
Net margin
31.4%
ROCE
11.1%

-31.2% over the last year

TransMedics Group, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+14.0%
3M
-6.2%
6M
+25.4%
1Y
-31.2%
5Y
+274.1%

52-week range

Day change -$8.77 (-9.3%) from $94 to $85 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TMDX, bought on each weekday since 2021.

News & filings

What TransMedics Group filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity of 40.2% against a peer median of 5.8%.

Concerns (1)

  • The price fell as much as 59% from a high within the last year.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Read moreShow less

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Sector
Healthcare
Shares outstanding
34.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.5B
P/E
13.0x
P/B
5.2x
EV / EBITDA
16.8x
EV / Sales
4.1x
P/S
4.1x
52-week high
$150.42
52-week low
$62.04

Profitability

Operating margin
17.9%
Net margin
31.4%
EBITDA margin
24.5%
ROE
40.2%
ROCE
11.1%
ROA
17.8%
Asset turnover
0.57

Growth

Revenue
$605.5M
Revenue growth, 1Y
37.1%
Revenue CAGR, 3Y
86.4%
Net profit growth, 1Y
436.6%
Free cash flow
$133.6M

Solvency

Current ratio
7.14
Debt / Equity
1.10
Debt / Assets
0.49
CFO / Net profit
1.01
Cash / Market cap
19.8%

Where the revenue went

Of every $100 of FY2025 revenue, $31 was left as net income.

TransMedics Group, Inc. income statement flow, FY2025
TransMedics Group, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$242.7M
RevenueGross profit$362.8M
Gross profitOperating expenses$254.2M
Gross profitOperating income$108.6M
Operating incomePretax income$107.5M
Operating incomeInterest and other expense$1.1M
Pretax incomeNet income$107.5M
Tax benefit and otherNet income$82.8M

Revenue and net profit

Revenue grew 37.1% in FY2025; net profit is the dashed line.

TransMedics Group, Inc. revenue and net profit by fiscal year
TransMedics Group, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$93.5M-$36.2M
FY2023$241.6M-$25.0M
FY2024$441.5M$35.5M
FY2025$605.5M$190.3M

Cash flows

FY2025: $192.8M from operations, $133.6M free after investment (dashed).

TransMedics Group, Inc. operating and free cash flow by fiscal year
TransMedics Group, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$45.8M-$57.7M
FY2023-$13.0M-$192.1M
FY2024$48.8M-$80.9M
FY2025$192.8M$133.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$605.5M+37.1%1Y
EBITDA
$148.5M+112.3%1Y
Net profit
$190.3M+436.6%1Y
Cash from operations
$192.8M+295.1%1Y
Free cash flow
$133.6M
Revenue CAGR, 3Y
86.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$605.5M$148.5M$190.3M$133.6M40.2%+37.1%+436.6%

Monthly returns

Month-by-month returns of TMDX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$595.3M
Equity$473.1M
Retained earnings-$277.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TMDX highlighted.

P/E against peers

TMDX trades at 13.0x earnings against a peer median of 12.6x.

Not shown (no positive earnings and no EV / Sales): Supernus Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., Neogen Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
TransMedics Group, Inc.TMDXthis company$2.5B13.0x5.2x40.2%16.8x
National HealthCare CorporationNHC$2.9B24.5x2.7x11.2%13.7x
Privia Health Group, Inc.PRVA$2.7B117.5x3.7x3.1%50.4x
Supernus Pharmaceuticals, Inc.SUPN$2.6B-67.3x2.4x-3.6%58.9x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Neogen CorporationNEOG$2.0B-1.8x1.0x-52.7%-2.9x
Peer median—12.6x1.8x5.8%11.6x

Year-to-date ROI

TMDX since 1 January, against earlier years.

Historical volatility

TMDX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

TransMedics Group, Inc. operating margin by fiscal year
TransMedics Group, Inc. operating margin by fiscal year
DateOperating margin
FY2022-33.6%
FY2023-11.9%
FY20248.5%
FY202517.9%
LineFY2025
Cost of revenueCost Of Revenue$242.7M
Gross profitGross Profit$362.8M
Operating expensesOperating Expense$254.2M
Research and developmentResearch And Development$69.1M
Total expensesTotal Expenses$496.9M
Pretax incomePretax Income$107.5M

Learn while you research

Academy chapters picked for TransMedics Group, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing37% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →